Pancreatic Cancer Research

ResearcherJichi Medical UniversityActive in the last 2 years

Koetsu Inoue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-9009-3084; OpenAlex author ID A5062994985. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 4 papers

Papers 9

  1. Duke Pancreatic Monoclonal Antigen Type 2 for Monitoring Carbohydrate Antigen 19-9 Nonexpressor Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2026.1810↗
  2. Survival Impact After Resection for Postoperative Recurrence or Metastasis of Pancreatic Ductal Adenocarcinoma Analyzed Using a Time-Dependent Cox Regression M… Co-author DOI 10.1002/jhbp.70054↗
  3. Histological treatment response to neoadjuvant chemotherapy predicts the survival outcomes of patients with resectable pancreatic cancer: validation of the Jap… Co-author DOI 10.1007/s00595-026-03325-w↗
  4. DNA Hypomethylation in Pancreatic Cancer Tissues Before Treatment, Defined by KRAS -mutated Circulating Tumor DNA, is Associated With Poor Prognosis. Co-author DOI 10.1097/mpa.0000000000002650↗
  5. Preoperative Chemotherapy With Gemcitabine for Pancreatic Cancer Causes Zinc Deficiency. Co-author DOI 10.1097/mpa.0000000000002396↗
  6. Favorable Response Defined by CA19-9 Reduction After Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18084-0↗
  7. Collagen XVII regulates tumor growth in pancreatic cancer through interaction with the tumor microenvironment. Co-author DOI 10.1111/cas.15952↗
  8. CA19-9 With Two-stage Resection Is Useful for Conversion Surgery in PDAC With Synchronous Oligometastases. Co-author DOI 10.21873/anticanres.16724↗
  9. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kina… Co-author DOI 10.1016/j.ejps.2017.02.021↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masamichi Mizuma · 7 shared papers, 2023–2026 · strength 1.35
  2. Michiaki Unno · 7 shared papers, 2017–2026 · strength 1.23
  3. Masahiro Iseki · 4 shared papers, 2023–2026 · strength 0.75
  4. Shuichi Aoki · 4 shared papers, 2023–2026 · strength 0.75
  5. Fuyuhiko Motoi · 4 shared papers, 2023–2026 · strength 0.75
  6. Shimpei Maeda · 3 shared papers, 2023–2026 · strength 0.60
  7. Daisuke Douchi · 3 shared papers, 2023–2026 · strength 0.60
  8. So Yamaki · 3 shared papers, 2025–2026 · strength 0.60
  9. Sohei Satoi · 3 shared papers, 2025–2026 · strength 0.60
  10. Teiichi Sugiura · 3 shared papers, 2025–2026 · strength 0.60
  11. Kenjiro Okada · 3 shared papers, 2025–2026 · strength 0.60
  12. Atsushi Oba · 3 shared papers, 2025–2026 · strength 0.60
  13. Daisuke Hashimoto · 3 shared papers, 2025–2026 · strength 0.60
  14. Kenichiro Uemura · 3 shared papers, 2025–2026 · strength 0.60
  15. Katsuhisa Ohgi · 3 shared papers, 2025–2026 · strength 0.60
  16. Satoshi Hirano · 3 shared papers, 2025–2026 · strength 0.60
  17. Mitsuhiro Shimura · 2 shared papers, 2025–2026 · strength 0.45
  18. Yosuke Inoue · 2 shared papers, 2026 · strength 0.41
  19. Ryuta Shintakuya · 2 shared papers, 2026 · strength 0.41
  20. Daisuke Ban · 2 shared papers, 2026 · strength 0.41
  21. Nobuhiko Nakagawa · 2 shared papers, 2026 · strength 0.41
  22. Kojiro Omiya · 2 shared papers, 2025–2026 · strength 0.39
  23. Takashi Kokumai · 2 shared papers, 2023–2025 · strength 0.36
  24. Kei Nakagawa · 2 shared papers, 2023–2025 · strength 0.36
  25. Yuhei Endo · 1 shared paper, 2026 · strength 0.28

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.